Latest news

• Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit

  Overall, HIV product sales decreased by 12% to $3.7bn for the first quarter, although sales of its newer HIV treatment Biktarvy increased by 8% year-on-year in Q1.

• GSK considers more divestments to help R&D push

  Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) product.

• FDA rejects ViiV’s long-acting monthly HIV injection

  ViiV’s rival Gilead was the first company to bring a single-tablet triple therapy – Biktarvy – to market, and the former has been desperately pushing its own two-drug oral therapies ... Gilead’s Biktarvy has grown quickly since its launch last

• ViiV builds case for switching to its two-drug HIV combinations

  Taking aim at rival Biktarvy. ViiV Healthcare says it has data that shows people with HIV can safely switch from Gilead's three-drug therapies to one of its two-drug ... For comparison, Biktarvy brought in $739m in sales in the first quarter of the year,

• ViiV bags EU okay for new two-drug HIV therapy

  Rivals Gilead's Biktarvy. ViiV Healthcare now has approval on both sides of the Atlantic for two-drug HIV therapy Dovato after a green light from the EMA. ... Dovato was approved in the US in April as a single-tablet, once-daily regimen for